IncobotulinumtoxinA (Xeomin) injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders

This page provides the factsheet for new MBS item 18355 for the treatment of chronic sialorrhea treatment due to neurological or neurodevelopmental disorders.

Page last updated: 05 February 2026

From 1 March 2026, item 18355 will be introduced to allow for the injection of IncobotulinumtoxinA (Xeomin) for patients with chronic sialorrhea due to neurological or neurodevelopmental disorders. The listing of this service was recommended by the Medical Services Advisory Committee (MSAC) in April 2025.

Further information is available in the factsheet below:

Word version - Xeomin injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders.DOCXWord version - Xeomin injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders.DOCX

PDF version - Xeomin injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders.pdfPDF version - Xeomin injection for chronic sialorrhea treatment due to neurological or neurodevelopmental disorders.pdf

In this section